Login / Signup

Efficacy and safety of a new 5% minoxidil formulation in male androgenetic alopecia: A randomized, placebo-controlled, double-blind, noninferiority study.

Ulrike Blume-PeytaviZahida IssiakhemStephanie GautierJan KottnerWalter Wigger-AlbertiTobias FischerRolf HoffmannFrançoise TonnerAthmane BouroubiJean-Jacques Voisard
Published in: Journal of cosmetic dermatology (2018)
DC0120 was as safe and effective as a similar marketed minoxidil product for stimulating hair growth in men with AGA.
Keyphrases
  • placebo controlled
  • double blind
  • clinical trial
  • phase ii
  • phase iii
  • drug delivery
  • dendritic cells
  • phase ii study
  • randomized controlled trial
  • squamous cell carcinoma
  • immune response
  • middle aged
  • platelet rich plasma